Clarivate is betting that a narrower company is a stronger one. The July 2026 agreement to sell Life Sciences and Healthcare to Altaris for $600 million would leave Clarivate concentrated on Academia and Government plus Intellectual Property, funding debt reduction from the proceeds. The same quarter, Q2 2026 revenue fell 5.5%, organic revenue fell 1.5%, and the company took a $221.7 million goodwill impairment charge.
One thing worth flagging: management has tied the plan to specific, falsifiable outcomes, including higher recurring revenue mix, positive organic ACV growth, and margin expansion to 42% or higher by year end. With transactional revenue down 30.1% in the same quarter the divestiture was announced, the plan's credibility depends on the core business turning a corner that has not yet shown up in the numbers. This Dossier lays out what would resolve each question, and why neither is settled by the public record alone.
Sources and Methods
Dossiers are built from primary documents: SEC filings, earnings call and investor day transcripts, management presentations, press releases, and trade press. We also work the channels where product and operating problems surface before they reach an earnings call, including App Store, Google Play, and Trustpilot reviews, and structured sentiment research on Reddit Answers. Equity analyst commentary is used to map where the sell side disagrees and is treated as opinion, not evidence.
The Intelligence Council is editorially independent. No company reviews a Dossier before publication.
The Dossier is for the people who run the education ecosystem: institutional leaders, workforce and L&D buyers, and the founders, investors, and GTM executives who sell to them.
Ping us at [email protected] if you’d like to learn more, explore Enterprise Access, or would like to partner in other ways.
The Intelligence Council is a next-gen B2B media and business intelligence platform built for people who make strategy, allocate capital, and carry operating risk.